Secukinumab
- Generic Name
- Secukinumab
- Brand Names
- Cosentyx
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1229022-83-6
- Unique Ingredient Identifier
- DLG4EML025
- Background
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Fo...
- Indication
Secukinumab is indicated the treatment of moderate to severe plaque psoriasis in patients six years and older who are candidates for systemic therapy or phototherapy. In Europe, the drug is used in children and adolescents six to 18 years of age for this indication.
...
- Associated Conditions
- Enthesitis Related Arthritis (ERA), Juvenile Idiopathic Arthritis (JIA), Juvenile psoriatic arthritis, Non-radiographic Axial Spondyloarthritis, Severe Plaque psoriasis, Active Ankylosing spondylitis, Active Psoriatic arthritis, Moderate Plaque psoriasis
- Associated Therapies
- -
Secukinumab Efficacy Without the Initial Loading Dose in Patients With Psoriasis
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Universita di Verona
- Target Recruit Count
- 156
- Registration Number
- NCT03828643
- Locations
- 🇮🇹
University of Verona, Verona, Italy
Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)
- First Posted Date
- 2019-01-02
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 4
- Registration Number
- NCT03791060
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 545
- Registration Number
- NCT03713619
- Locations
- 🇬🇧
Novartis Investigative Site, Norwich, United Kingdom
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 545
- Registration Number
- NCT03713632
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
PsA Secukinumab XCT Structural Progression Study
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 40
- Registration Number
- NCT03623867
- Locations
- 🇭🇰
Department of Medicine and Therapeutics, Hong Kong, Hong Kong
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 743
- Registration Number
- NCT03536884
- Locations
- 🇩🇪
Ps0015 222, Tuebingen, Germany
🇵🇱Ps0015 355, Bialystok, Poland
🇹🇷Ps0015 763, Gaziantep, Turkey
A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1484
- Registration Number
- NCT03535194
- Locations
- 🇦🇺
Clinical Trials SA Pty Ltd, Adelaide, South Australia, Australia
🇺🇸Dawes Fretzin Clinical Research, Indianapolis, Indiana, United States
🇺🇸Dermatology Associates, Seattle, Washington, United States
Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 327
- Registration Number
- NCT03478787
- Locations
- 🇨🇦
Beacon Dermatology Inc /ID# 203054, Calgary, Alberta, Canada
🇫🇷Hopital Saint-Louis /ID# 203586, Paris, France
🇺🇸Progressive Medical Research /ID# 202183, Port Orange, Florida, United States
Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis
- Conditions
- Interventions
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2024-11-18
- Target Recruit Count
- 300
- Registration Number
- NCT03445845
- Locations
- 🇫🇷
CHU d'Angers, Angers, France
🇫🇷CHRU Besançon, Besançon, France
🇫🇷APHP- Hôpital Avicenne, Bobigny, France
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 781
- Registration Number
- NCT03440736
- Locations
- 🇩🇪
Novartis Investigative Site, Wuppertal, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.